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Chinese Journal of Cancer

Conference Report

Juan Cui1, Yan鄄 Chun Liang2 and Ying Xu1,2
Abstract
The report summarizes the Second International Workshop of Cancer Systems Biology held on July 5-6,
2012 in Changchun, China. The goal of the workshop was to bring together cancer researchers with different
backgrounds to share their views about cancer and their experiences in fighting against cancer, and to gain
new and systems鄄level understanding about cancer formation, progression, diagnosis, and treatment through
exchanging ideas.

The Second International Workshop of Cancer
Systems Biology (ICSB) (http://ccst.jlu.edu.cn/icsb2012/),
hosted by Jilin University, was held from July 5 to 6,
2012 in Changchun, China. During this twoday meeting,
21 invited speakers, 7 from China, 13 from the United
States, and 1 from Canada, gave speeches covering a
wide range of topics on cancer systems biology to an
audience of approximately 300 people from across
China. The 21 talks roughly fell into four categories:
cancer genome analysis and information discovery,
cancer mechanism studies, biomarker discovery, and
cancer treatment strategies. By design, these talks were
delivered by cancer researchers and practitioners with
diverse backgrounds who may not otherwise have
opportunities to meet and share their visions about
cancer studies in an open and scientifically stimulating
environment. Among the speakers were cancer
biologists who study specific cancer pathways,
computational cancer biologists who rely on largescale
data for global information discovery, computational
modelers who examine dynamic properties of cancer,
immunologists who study cancer in a larger context than
just tumors, and clinicians who use different strategies
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and techniques to treat cancer patients. Having such a
diverse group of people speaking to each other and to
an audience with an even wider range of expertise
generated much excitement. At the end of the meeting,
virtually all speakers and many attendees expressed
praise for the workshop as one of the best they had
attended, having been impressed by the overall quality of
the talks and the intellectual level of the dialog it created.
This meeting, which is the second in its series, was
initiated by Professor Ying Xu (University of Georgia and
Jilin University) and Professor YanChun Liang (Jilin
University) in early 2011. The overall consideration in
organizing this annual meeting is to bring together
cancer researchers with different backgrounds to share
their views and experiences in fighting cancer and to
gain new systemslevel understanding of cancer
formation, progression, diagnosis, and treatment through
exchanging ideas. Professor Liang Hu, Dean of the
College of Computer Science and Technology at Jilin
University, generously agreed to financially sponsor the
first three annual meetings of this series, which has
made this and the previous meeting possible. Like in the
first meeting in 2011, the organizers felt very fortunate
for the opportunity to bring together this group of leaders
in their respective research areas to present their
science and lead discussions.

Cancer Genome/Epigenome Sequencing
and Information Discovery
To understand the genetic basis of cancer, two large
cancer genome sequencing projects have been initiated:
one by the International Cancer Genome Consortium
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and the other by the US National Cancer Institute and
National Human Genome Research Institute, named The
Cancer Genome Atlas (TCGA). TCGA aims to develop a
complete 野 atlas 冶 of all genomic alterations involved in
dozens of major cancer types. Dr. Wei Zhang (MD
Anderson Cancer Center), a principal investigator of the
TCGA Initiative, presented a study by his group on the
implications of
and
mutations on ovarian
cancer prognosis. They found that
mutated
ovarian cancers have higher levels of gene mutations,
respond better to frontline therapy, and have a longer
overall and progressionfree survival. In addition, he also
discussed their recent genome sequencing study of
colorectal cancer, which was published in the July 2012
issue of
, as well as their bioinformatic analyses
on endometrial cancer that revealed three distinct
subtypes with distinct pathway level characteristics.
Dr. Juan Cui (University of Georgia) introduced her
group爷 s recent study in which the whole genomes of five
gastric adenocarcinomas and matching controls were
sequenced. The density of the mutation spectrum of
each cancer genome ranged from 6.8 to 13.8 mutations
per Mb of DNA. In total, 407 nonsynonymous somatic
point variations were identified, primarily occurring in
mucins and transcription factors. Seventysix genes had
copynumber changes, and 679 genomic rearrange鄄
ments were detected. The study revealed that 79.6% of
the chromosomal rearrangements occurred among
neighboring regions in the folded chromosomes, based
on mapping of the boundaries of the rearranged regions
to the folded threedimensional structures of the human
chromosomes and the replication timing profiles.
In his presentation, Dr. JinTang Dong (Emory
University) demonstrated how a tumor suppressor gene
can be identified from a chromosomal region that is
frequently deleted in human cancer. Specifically, he and
his colleagues presented krueppellike factor 5 (KLF5) as
a tumor suppressor gene based on
and
studies and reported a novel mechanism for how KLF5
can be inactivated in human cancer. Interestingly, animal
studies demonstrated that KLF5 can act as both a tumor
suppressor and promoter, and biochemical analyses of
cultured epithelial cells revealed a possible mechanism
for how KLF5 can switch functions. In their
studies, Dr. Dong 爷s group found that KLF5 is a cofactor
of TGF茁 signaling, and TGF茁induced acetylation of
KLF5 is the key event that reverses the function of
KLF5. In the absence of TGF茁, KLF5 is not acetylated
and promotes cell proliferation by regulating cell cycle
genes. However, when TGF茁 is present, KLF5 is
acetylated and the acetylation reassembles the KLF5
transcriptional complex, leading to a change in gene
transcription and the reversal of KLF5 function.
DNA methylation is associated with silencing or
overexpression of many biologically important genes in
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almost all types of cancer. Dr. Dong Xu (University of
Missouri) described his group爷 s bisulfitesequencing
analysis of DNA methylation patterns across different
cancer tissue samples. They identified digital profiles of
aberrant DNA methylation and suggested potential
methylation biomarkers for cancer subtypes. They also
studied sequence and methylation patterns among DNA
methyltransferases and found longrange patterns in the
flanking sequences around methylation sites and
cooperativity among different DNA methyltransferases. In
addition, they found that DNA methylation in the 3'UTR
was positively correlated with expression of the upstream
gene, in contrast to negative correlation of expression
with its promoter region. Their analysis indicates that 3'
UTRs are hypomethylated in tumor samples and that
genes with longer 3'UTRs tend to have more differential
methylation and thus a higher ability to regulate the gene
expression.
In addition, Dr. WenYi Wang (MD Anderson Cancer
Center) also presented her work on cancer genome
analyses and applications.

Mechanisms of Cancer
Four talks were focused on mechanisms of cancer.
Speakers discussed the topic from their own unique
perspectives, some with a more traditional focus on
specific cancerrelated pathways and others with a focus
on global pictures.
Dr. Ying Xu (University of Georgia) presented a
model showing that hypoxia may serve as a key driver
for cancer growth. The idea of the model is that as a cell
becomes increasingly more hypoxic, there is a switch in
cellular respiration from oxidative phosphorylation to
glycolysis, which was first reported 90 years ago by Otto
Warburg. Such a switch in energy metabolisms leads to
decreased generation of ATP per glucose and results in
increased glucose uptake by the affected cells, a
phenomenon that is widely observed through cancer
imaging data. The increased accumulation of glucose is
due to the fact that the outgoing rates of carbons through
lactate and the electron transport chain are significantly
lower than incoming rates of carbons from the glucose.
The accumulated glucose/intermediates must be cleared
or cells will die. Cells have evolved to adopt the process
of biosynthesis to relieve this carbon burden, which
gradually leads to systematic changes in cellular
metabolism and ultimately results in the synthesis of new
cells. This cycle accelerates as the cell population
becomes increasingly more hypoxic and forms a
selfpropelling cycle driven by the force to remove
excess carbons. This model is consistent with the large
scale transcriptomic data.
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Evasion of apoptosis is one of the key hallmarks of
cancer and a major target of cancer therapy. Dr.
ShiYong Sun (Emory University) discussed death
receptor 5 (DR5), a cell surface proapoptotic death
receptor for tumor necrosis factorrelated apoptosis
inducing ligand (TRAIL). Oncogenic mutations of Ras
and BRaf frequently occur in cancer and are critical to
cell transformation and tumorigenesis. In their recent
study, Dr. Sun and colleagues forced expression of
oncogenic Ras or BRaf
and demonstrated that
these proteins positively regulate DR5 expression. This
finding is further supported by results showing that
knockdown of endogenous KRas or BRaf reduced the
expression of DR5. Importantly, they also showed that
Ras induced DR5 expression through coactivation of the
ERK/RSK and JNK signaling pathways and subsequent
cooperative effects among the transcriptional factors
CHOP, Elk1, and cJun.
In addition, Dr. Zhiren Luis Liu (Georgia State
University) and Dr. Xiaole Shirley Liu (Harvard University
and DanaFarber Cancer Institute) also presented their
work.

Search for Biomarkers for Cancer
Subtyping, Diagnosis, and Prognosis
There were six talks on the identification and
application of biomarkers. Dr. YaPing Tian (Beijing 301
Hospital) described his group爷 s study of the peripheral
blood from which they identified an 8gene panel that
could be used to distinguish blood samples of hepatitis
B, liver cirrhosis, and hepatocellular carcinoma patients
from those of healthy donors with high statistical
significance. Based on this study, they have developed a
peripheral blood gene expression profiling test (GeXP)
for differential diagnosis of hepatic diseases.
Dr. ChaoNan (Miles) Qian (Van Andel Research
Institute and Sun Yatsen University Cancer Center)
presented his team 爷s finding that the secreted molecules
serglycin and interleukin8 (IL8) promote metastasis of
nasopharyngeal carcinoma (NPC) cells through autocrine
and paracrine mechanisms and serve as independent
prognostic factors for the survival of NPC patients. They
found that IL8 can induce the expression of many
mesenchymal markers and suppress the expression of
epithelial markers. Clinically, cancer cells with a high
propensity for metastasis are the primary cause of
patient death. However, these cells may be present in
very low numbers in primary tumors, hence making gene
expression profiling a major challenge. Therefore, as Dr.
Qian 爷s group demonstrated through their studies, using
parental cells to isolate metastatic clones may be a
useful strategy to overcome this challenge and allow
identification of the prometastatic gene expression
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signature by gene expression profiling.
Dr. Bing Zhang (Vanderbilt University) discussed his
group爷 s work on identifying prognostic markers for
colorectal cancer. They investigated eight published
colorectal cancer gene expression signatures. Using a
random walkbased approach, they integrated these
signatures and publicly available somatic mutation data
on a proteinprotein interaction network and inferred 487
genes as plausible candidate molecular underpinnings
for the colorectal cancer recurrence phenotype. The
resultant list of genes was deemed an NEM signature.
An NEM signaturebased survival support vector
machine prognostic model was trained using a gene
expression dataset and tested on an independent
dataset. The modelbased scores were 75.7%
concordant with patient survival data and separated
patients into two groups with significantly different
relapsefree survival ( = 0.002). Furthermore, adjuvant
chemotherapy
was
significantly
associated
with
prolonged survival of the highrisk patients ( = 0.006)
but not beneficial to the lowrisk patients ( = 0.491).
Thus, the NEM signature not only reflects colorectal
cancer biology but also informs patient prognosis and
treatment response.
The other biomarker talks were focused on existing
techniques for biomarker identification. For example, one
major problem is that most biomarkers cannot be
reproducibly identified by independent studies. To
address this, Dr. Zheng Guo (Harbin Medical University)
proposed a new strategy of using scores to evaluate the
functional reproducibility of cancer biomarkers based on
molecular models that take into account the functional
associations among the marker genes/proteins. The
biological assumption underlying a score is statistically
testable to explain the diverse but functionally related
biomarker genes/proteins. Dr. Guo reported that
biomarkers identified using this method could be
reproducibly detected when using different omic
datasets.
Another serious issue is that while both molecular
and network biomarkers can be used to distinguish
disease samples from normal samples, neither are
guaranteed to successfully identify predisease samples
due to their static nature. Thus, these markers are not
useful for early diagnosis. In a departure from traditional
approaches, Dr. LuoNan Chen (Chinese Academy of
Sciences, Shanghai) has recently developed a new
theory of dynamical network biomarkers (DNBs) based
on nonlinear dynamical theory and network theory.
Applying this theory, Dr. Chen and his research team
showed for the first time that DNBs can distinguish the
predisease state from the normal state, even with small
numbers of samples, and therefore have a great
potential to achieve 野 real 冶 early diagnosis of complex
diseases like cancer.
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Dr. Edwin Wang (National Research Council Canada
and McGill University) showed that alterations of tumor
suppressor genes are essential to cancer development
and progression. Mutation of tumor suppressor genes
often increases genomic instability, which makes
passenger, or nonspecific, signals more common in
tumor cells than in other cell types and causes variability
in the gene expression profiles between individual
tumors. Thus, the 野 real 冶 cancer gene expression signals
may be buried in these highly varied profiles. These
insights prompted Dr. Wang and colleagues to develop a
new algorithm that focuses on functional modules
instead of network modules, which are limited by a lack
of comprehensive network data. These functional
modules provide several advantages as they (1) reduce
potential passenger signals; (2) overcome the well
known overfitting problems; and (3) make the effects of
the biomarkers more stable due to the functional
interactions between the genes in a functional module.
As proofofconcept, they successfully applied the
algorithm and identified breast cancer prognostic
biomarkers that could identify lowrisk patient in eight
independent cohorts containing more than 1300 patients.
Dr. Shyr Yu (Vanderbilt University) also presented a
talk about issues with the existing methods commonly
used in bioinformatics studies and offered new solutions.

eradicated the directly injected melanoma tumors but
also caused regression of collateral melanoma tumors in
2 out of 19 patients with intransit melanoma in a phase I
trial by Adil Daud. Dr. ShuLin Li (MD Anderson Cancer
Center) reported that he and his colleagues generated a
tumortargeted IL12 that is more effective than wildtype
IL12 in inhibiting metastatic tumors. He also showed
results of their study in which the IL12 gene and
chemical
medicine
were
coadministered
via
electroporation to treat recurrent and largevolume
squamous cell carcinoma in dogs. The central hypo鄄
thesis behind this coadministration approach is that
chemotherapy delivered by electroporation will cause
tumor cell death and release of tumor antigens, while
IL12 gene therapy delivered by electroporation will
recruit and stimulate immune cells to process the
released antigens to generate an antitumor immune
memory. The success in causing tumor regression in
dogs provides solid evidence to support this hypothesis.
Dr. YaJun Guo, Dr. XiaoNing Wang, and Dr. Ying
Gu, all from Beijing 301 Hospital, also presented their
experience in treating cancers using different techniques
and strategies.

Drug Targets and Cancer Treatment
Strategies

Forty years have passed since the declaration of
the 野 war on cancer冶 in the early 1970s. While
considerable progress has been made in our overall
ability to fight this disease, cancer remains the second
leading cause of death worldwide. The reality is that we
are still far from reaching the goal set 40 years ago. The
general consensus in the field has been that
fundamentally new ways to study cancer should be
developed based on the lessons learned in the past. We
aimed to use this meeting series to bring together
researchers who have been studying cancer from very
different perspectives to develop novel views, ask deeper
questions about the essence of cancer, and generate
new dialogs/collaborations leading to fundamentally new
understanding about cancer at the systems level.

In his talk, Dr. WeiPing Zou (University of
Michigan) focused on Th17 cells in the tumor
microenvironment. Th17 cells phenotypically resemble to
terminally differentiated memory T cells, but are different
from central memory, exhausted and senescent T cells.
His group demonstrated that Th17 cells mediate and
promote longterm antitumor immunity. Furthermore,
Th17 cells have stem celllike features including high
capacity of proliferative selfrenewal, potent persistence
and apoptotic resistance
, and the generation of
other types of T helper cells. Moreover, the stem celllike
characteristics of these cells are regulated by the
signaling pathways of hypoxiainducible factor 1琢 (HIF1琢)
and Notch. Thus, Th17 cells may be a longlived
proliferating T cell population with stem cell charac鄄
teristics, which may be important determinants in Th17
biology. Therefore targeting the Th17 stemness would be
therapeutically meaningful for treating patients with
chronic diseases affected by Th17 cells
Electroporation is becoming a powerful and yet very
simple drug delivery tool for cancer treatment.
Administration of DNA encoding IL12 has not only
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